

Humanigen, Inc.

21:31 22 Jul 2019

Humanigen bolsters treatment of graft-versus-host disease in leukemia patients via licensing agreement with the University of Zurich

Humanigen Inc (OTCMKTS:HGEN) has a new tool in its box to prevent graft-versus-host disease when treating patients with leukemia and other blood cancers.

The Burlingame, California-based company announced Monday that it has received an exclusive licensing agreement from the University of Zurich in Switzerland to utilize its GM-CSF protein neutralization technology.

The agreement is a boon to Humanigen's development of a treatment called allogeneic hematopoietic stem cell therapy, which uses donor T cells to combat blood cancers in a process known as graft-versus-leukemia.

The problem is that the donor cells can also destroy healthy tissue by producing the protein GM-CSF, resulting in graft-versus host disease, which kills 50% of patients who contract it.

WATCH: Humanigen teams up with Kite to treat a type of lymphoma cancer That's where the University of Zurich's neutralization technology comes into play. A recent article in the journal of Science Translational Medicine demonstrated that negating the GM-CSF protein can cut down the harmful graft-versus-host while preserving the helpful graft-versus-leukemia.

The discovery significantly expands Humanigen's intellectual property portfolio in preventing graft-versus-host disease.

"Humanigen has pioneered the strategy of neutralizing GM-CSF to improve the safety and efficacy of T cell therapies," CEO Cameron Durrant said. "This license agreement builds on our leadership position aimed at breaking the efficacy/toxicity barrier that currently exists for T cell therapies, including allogeneic HSCT."

The company's stock was flat Monday at \$1.05.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Price: 0.4

Market Cap: \$45.11 m

1 Year Share Price Graph



December 2018 May 2019 December 20

Share Information

Code: HGEN

Listing: OTCQB

52 week High Low
1.544 0.38

Sector: Pharma & Biotech

Website: www.humanigen.com

Company Synopsis:

Humanigen develops biologics to improve CAR-T and other breakthrough oncology treatments. Lenzilumab is a product that has the potential to both improve the efficacy and safety associated with CAR-T therapy in oncology. We are developing lenzilumab in close collaboration with the leading and most experienced centers in the CAR-T field. We are exploring partnerships with established and emerging CAR-T companies.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).